Exelixis (EXEL) Receives a Buy From Wells Fargo
Exelixis: Balancing Strong Financials With Operational Challenges in Berens's Hold Rating
Exelixis Price Target Raised to $29.00/Share From $27.00 by JMP Securities
RBC Capital Reiterates Outperform on Exelixis, Maintains $27 Price Target
Exelixis Analyst Ratings
Exelixis's Strong Q2 Financials and Strategic Pipeline Prompts a Buy Rating
Piper Sandler Reaffirms Their Buy Rating on Exelixis (EXEL)
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
Exelixis Analyst Ratings
Oppenheimer Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $29
Exelixis (EXEL) Gets a Hold From Barclays
JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $27
Exelixis Buy Rating Affirmed on Q2 Outperformance and Positive Litigation Outlook
Morgan Stanley Sticks to Their Hold Rating for Exelixis (EXEL)
Bank of America Securities Reaffirms Their Buy Rating on Exelixis (EXEL)
Buy Rating for Exelixis: Navigating Patent Lifecycles and Bolstering Growth With a Robust Pipeline
Exelixis Analyst Ratings
Exelixis Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $28 Price Target
Hold Rating on Exelixis: Analyzing Q1 Revenue Shortfalls and Pipeline Progress